|
gptkbp:instanceOf
|
gptkb:chemical_compound
antineoplastic agent
purine analog
immunosuppressive agent
|
|
gptkbp:administeredBy
|
phosphate salt
|
|
gptkbp:approvalYear
|
1991
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
L01BB05
|
|
gptkbp:CASNumber
|
21679-14-1
|
|
gptkbp:category
|
antineoplastic agent
immunosuppressant
purine analog
|
|
gptkbp:chemicalFormula
|
C10H12FN5O4
|
|
gptkbp:contraindication
|
pregnancy
severe renal impairment
|
|
gptkbp:discoveredBy
|
gptkb:John_Montgomery
|
|
gptkbp:eliminationHalfLife
|
10 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
fludarabine
|
|
gptkbp:KEGGID
|
D00457
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits ribonucleotide reductase
inhibits DNA synthesis
|
|
gptkbp:metabolism
|
dephosphorylation
|
|
gptkbp:molecularWeight
|
285.23 g/mol
|
|
gptkbp:origin
|
synthetic
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:PubChem_CID
|
CHEMBL1377
10482154
135398744
DB01073
|
|
gptkbp:riskFactor
|
gptkb:autoimmune_hemolytic_anemia
opportunistic infections
neurotoxicity
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
|
|
gptkbp:sideEffect
|
fever
nausea
vomiting
immunosuppression
fatigue
increased risk of infection
myelosuppression
|
|
gptkbp:synonym
|
gptkb:2-fluoro-ara-AMP
gptkb:Fludara
gptkb:fludarabine_phosphate
|
|
gptkbp:UNII
|
G9H3U5XWQK
|
|
gptkbp:usedFor
|
leukemia
chronic lymphocytic leukemia
|
|
gptkbp:bfsParent
|
gptkb:multidrug_resistance-associated_protein_1
|
|
gptkbp:bfsLayer
|
6
|